Zobrazeno 1 - 10
of 157
pro vyhledávání: '"Kucukoner M"'
Autor:
Saip, P., Eralp, Y., Sen, F., Karaca, H., Ozkan, M., Cetin, B., Benekli, M., Kucukoner, M., Isikdogan, A., Un, O., Basaran, G., Onur, H.
Publikováno v:
In The Breast October 2013 22(5):628-633
Autor:
Kilickap, S., Ozturk, A., Karadurmus, N., Korkmaz, T., Yumuk, P., Cicin, I., Paydas, S., Cilbir, E., Sakalar, T., Uysal, M., Uskent, N., Demir, N., Sakin, A., Turhal, N., Keskin, S., Tural, D., Eralp, Y., Basal, F., Hatime Yasar, Sendur, M. A., Demirci, U., Cubukcu, E., Karaagac, M., Karaca, S., Tatli, A., Yetisyigit, T., Urvay, S., Gursoy, P., Uluc, B. Oyan, Turna, Z., Kucukoner, M., Olmez, O., Cabuk, D., Seker, M., Unal, O., Meydan, N., Okutur, S., Tunali, D.
Publikováno v:
Web of Science
WOS: 000454014501235 Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We performed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::235bdde16c7aeb8cb59be61616c22dc2
https://hdl.handle.net/20.500.12511/1881
https://hdl.handle.net/20.500.12511/1881
Publikováno v:
In Journal of Thoracic Oncology October 2018 13(10) Supplement:S887-S887
Publikováno v:
In Journal of Thoracic Oncology October 2018 13(10) Supplement:S683-S684
Publikováno v:
Europe PubMed Central
Non-small cell lung cancer (NSCLC) makes up 80-85% of all lung cancers cases. Lung cancer in older individuals is frequently undertreated. Patients eligible for cisplatin- based chemotherapy should be selected carefully. The aim of this retrospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::bf9fa16ffd4bb204d7f34141c56c6515
https://pubmed.ncbi.nlm.nih.gov/23033295
https://pubmed.ncbi.nlm.nih.gov/23033295
Autor:
Dikiltas, M., Helvaci, K., Geredeli, C., Gumus, M., Kucukoner, M., Inal, A., Kos, F. T., Ozkan, M., Uncu, D., Buyukberber, S., Ozdemir, N., Goksel, G., Harputoglu, H., Durnali, A. G., Kaplan, M. A., Balakan, O., Dane, F., Benekli, M., Isikdogan, A., ÜNEK, İLKAY TUĞBA, Algin, E., Yildiz, R., Colak, D., ELKIRAN, EMİN TAMER
Publikováno v:
Neoplasma. 59(3)
The majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II and III trials suggest that the combination of gemcitabine and cisplatin (GemCis) response rates were higher than Gemcitabine (Gem) alone, however the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6e9dd7202562454f935b89e06b3a70f0
https://pubmed.ncbi.nlm.nih.gov/22329849
https://pubmed.ncbi.nlm.nih.gov/22329849
Autor:
Inal, A., Kos, F. T., Algin, E., Yildiz, R., Berk, V., Unek, I. Tugba, Colak, D., Kucukoner, M., Elkiran, E. Tamer, Helvaci, K., Geredeli, C., Dane, F., Balakan, O., Ali İnal, Durnali, A. Gok, Harputoglu, H., Goksel, G., Ozdemir, N., Buyukberber, S., Gumus, M., Ozkan, M., Benekli, M., Isikdogan, A.
Publikováno v:
Scopus-Elsevier
Web of Science
Web of Science
Purpose: The majority of patients with pancreatic cancer present with advanced disease. Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected caref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4c569887b4e0f92c59a824c31d709eb8
https://avesis.gazi.edu.tr/publication/details/c2ced8e4-a4c2-424c-88ff-7ae48abcd085/oai
https://avesis.gazi.edu.tr/publication/details/c2ced8e4-a4c2-424c-88ff-7ae48abcd085/oai
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.